Port Therapeutics pioneers a new category of spatiotemporal therapeutics designed to address localized disease problems. Their approach focuses on developing interventions that can be precisely activated at the required anatomical location and duration. This targeted activation strategy aims to maximize therapeutic effect while minimizing systemic exposure.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic treatments for localized diseases often lack the precision to target specific areas within the body, leading to off-target effects and reduced therapeutic efficacy. Current therapeutic approaches struggle to control the location and timing of drug activation, limiting their potential for treating a range of human diseases.
Solution
Port Therapeutics is developing spatiotemporal therapeutics, a novel class of treatments designed to be activated at specific locations and times within the body. By integrating synthetic biology and cell engineering with advanced clinical imaging techniques, Port aims to create therapies that can be precisely controlled and activated only in the diseased tissue. This targeted approach seeks to overcome the limitations of systemic treatments by enhancing precision, reducing off-target effects, and maximizing therapeutic impact. The company's technology platform enables the development of therapeutics that respond to specific stimuli, such as light or ultrasound, allowing for precise control over drug release and activation.
Target Audience
Port Therapeutics targets pharmaceutical companies and research institutions focused on developing innovative therapies for localized diseases, as well as patients seeking more effective and targeted treatment options.
Features
- Integration of synthetic biology, cell engineering, and clinical imaging for targeted drug delivery
- Development of therapeutics that can be activated at specific locations and times within the body
- Use of stimuli-responsive systems, such as light or ultrasound, to control drug release and activation
- Enhanced precision and reduced off-target effects compared to systemic treatments